ArticleInsights into imaging2026
Quantitative CT analysis in interstitial pneumonia with autoimmune features: diagnostic and prognostic insights from a retrospective cohort study.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe position of interstitial pneumonia with autoimmune features (IPAF) within the interstitial lung disease (ILD) spectrum remains unclear, with limited data regarding quantitative CT (QCT). This study aims to evaluate threshold-based QCT for distinguishing IPAF from other ILD subtypes and to assess the prognostic value of specific QCT features. MATERIALS AND
methodsIn this retrospective single-centre study, 227 patients (mean age 63.6 ± 12.8 years) with CTD-ILD (n = 123), IPAF (n = 54), or IPF (n = 50) diagnosed between January 2005 and October 2024 were included. QCT assessed ground-glass opacity (GGO), consolidation, emphysema, affected lung, and GGO-to-consolidation ratio. Group comparisons used adjusted general linear models; progression-free survival (PFS) was analyzed with Kaplan-Meier and Cox regression to identify QCT-based risk factors.
resultsLung consolidation was significantly higher in IPAF than in CTD-ILD (p = 0.046), while CTD-ILD showed higher GGO-to-consolidation ratios than IPAF (p < 0.001) and IPF (p = 0.009). IPAF had shorter PFS than CTD-ILD but longer than IPF. Higher GGO-to-consolidation ratios (HR 0.87, 95% CI: 0.79-0.97, p = 0.011) and higher emphysema percentage (HR 0.96, 95% CI: 0.93-0.99, p = 0.011) were associated with reduced progression risk, whereas the usual interstitial pneumonia pattern with higher risk in some lung compartments (e.g., lower third, HR 1.70, 95% CI: 1.07-2.71, p = 0.024). In the exploratory subgroup analysis, the GGO-to-consolidation ratio was associated with lower PFS in CTD-ILD only.
conclusionIPAF more closely resembled IPF in QCT features. The GGO-to-consolidation ratio emerged as a potential discriminative and prognostic factor. CRITICAL RELEVANCE STATEMENT: Threshold-based QCT provides reproducible diagnostic and prognostic biomarkers that help distinguish IPAF from other ILD subtypes and support risk stratification. KEY POINTS: Quantitative CT (QCT) has not been systematically investigated in interstitial pneumonia with autoimmune features (IPAF). QCT revealed distinct imaging and prognostic differences when comparing IPAF with other interstitial lung disease subtypes. QCT provides reproducible imaging biomarkers that aid IPAF differentiation and support clinical risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.